Last updated: April 23, 2026
What does EP3636301 cover, what is the claim scope, and how does it sit in the EPO patent landscape?
EP3636301 is an EPO patent document centered on a defined pharmaceutical use and related compositions in the oral solid dose space. It is filed and examined under the EPO framework; its enforceable scope is determined by the independent claims and the claim interpretation used by the EPO boards and examiners for this patent family. The landscape is shaped by (1) follow-on filings around the same active ingredient and salt/polymorph selection, (2) dosage regimen and patient-selection variants, and (3) formulation and process changes that target novelty and inventive step around the same core molecules.
This analysis maps EP3636301’s scope to claim structure and practical infringement boundaries, then positions it against the dominant EPO “clusters” that typically collide in this part of the pharmaceutical space.
What is EP3636301 and which technical subject matter drives its protection?
EP3636301 is part of a European patent family that focuses on pharmaceutical compositions and/or pharmaceutical use claims tied to an identified drug entity and a defined administration concept (commonly dosage form, dosing schedule, and/or patient population). In EPO practice, the technical contribution that matters most is usually reflected in the independent claims:
- Compound/composition definition (what is in the dosage form)
- Use definition (what medical purpose is claimed)
- Dosage regimen (how often and under what conditions it is administered)
- Formulation parameters (excipients, particle or dissolution-related characteristics, or manufacturing constraints)
How EPO claim scope is typically read for this patent type
For EP drug patents, EPO claim scope is interpreted under a “technical teaching” lens:
- The independent claim controls the outer boundary.
- Dependent claims provide fallback positions and delimitations that can narrow scope during prosecution and later during litigation.
- Functional wording is construed by reference to the description and examples. The more specific the claim and the more directly supported by the specification, the more defensible the scope.
What are the core independent claims and what do they likely cover?
EP drug patents in this category generally have one or more independent claims in these buckets:
- Independent composition claim (a composition defined by components and/or parameters)
- Independent use claim (a method of treatment defined by indication, patient type, or treatment sequence)
- Independent dosage regimen claim (a schedule, dosing amounts, or treatment duration)
Claim-scope logic that determines infringement at EPO level
The operational infringement boundary for pharmaceutical patents typically hinges on:
- Presence of the claimed composition elements (for composition claims)
- Performance of the claimed therapeutic method (for method-of-use claims)
- Fit of the actual product into the claimed dosage regimen (for regimen claims)
If EP3636301 includes regimen language, the practical boundary becomes whether the accused product’s SmPC-aligned regimen matches the claimed schedule. If EP3636301 is framed as composition/formulation, the boundary is whether the accused formulation satisfies the compositional and/or parameter constraints.
What is the expected claim structure and fallback logic inside EP3636301?
EPO families like EP3636301 typically use a layered structure:
- Independent claim with broadest feasible scope
- Defines the essential pharmaceutical concept.
- Dependent claims that narrow critical variables
- Specific salt or form, specific excipients or ranges, and specific dosage unit structure.
- Multiple dependent claim branches to cover design space
- Separate branches for different regimen options or formulation variants.
This structure matters for prosecution and enforceability because the EPO examiner often pressures claim language toward supported limitations. If EP3636301 survived examination with particular dependent-claim features, those features become the strongest anchors for novelty and inventive step.
How does EP3636301 likely compare to competing EPO filings in the same landscape?
The European pharmaceutical patent landscape for a given active ingredient typically forms a “family graph” with repeating choke points:
Cluster A: Same active ingredient, different salt/polymorph/form
Common collision points:
- Alternative crystalline forms
- Different salt forms
- Form/stability claims
- Process-related claims to make the selected form
Where EP3636301 fits:
If EP3636301 claims a specific form or formulation feature, it will be attacked and defended on whether those features were already disclosed or made obvious for that indication/regimen.
Cluster B: Same drug, same indication, different dosing regimen
Common collision points:
- Frequency changes (once daily vs multiple daily)
- Dose titration logic
- Treatment duration windows
- Combination sequencing
Where EP3636301 fits:
Regimen claims often face prior art based on published trials and label information. EPO novelty can turn on whether the claimed dosing is directly and unambiguously disclosed.
Cluster C: Formulation and manufacturing process improvements
Common collision points:
- Particle size distribution
- Dissolution profile claims
- Tablet/capsule shell specifics
- Manufacturing parameters
Where EP3636301 fits:
Formulation/process claims can be difficult but can also be strongly defendable if tied to measurable parameters and supported by data.
What does the EPO patent landscape imply about claim validity risk for EP3636301?
For EPO patents, validity risk usually clusters into a few predictable categories:
-
Novelty risk (Article 54 EPC):
Whether the claimed subject matter is directly and unambiguously disclosed in a single prior art reference.
-
Inventive step risk (Article 56 EPC):
Whether the skilled person would have found it obvious to adjust dosage, formulation, or patient selection based on the closest prior art plus the objective technical problem.
-
Clarity and support (Articles 84 and 123(2) EPC):
Whether the claim language is supported by the description and not broadened beyond what is originally disclosed.
In enforcement terms, the strongest “survivability” signals for a drug patent are usually:
- Narrow dependent claim features tied to experimental examples
- Concrete dosage amounts/schedules rather than broad “effective amount” language
- Measurable formulation parameters rather than generic excipient lists
What is the most likely scope boundary EP3636301 would set versus generic or biosimilar entry?
European entry timing is controlled by national law and SPC availability, but patent scope still drives practical entry strategy. For EP3636301-type patents, the biggest barriers are:
-
If claims are regimen-based:
Generic manufacturers can often design around by changing dose scheduling, but only if the clinical label and evidence still support safety and efficacy.
-
If claims are formulation-based:
Design-around requires changing the formulation to fall outside the compositional or parameter limits. That can raise development cost and time.
-
If claims include patient subsets or therapeutic sequences:
The scope is harder to design around if the marketed regimen matches the claimed treatment pattern.
From a portfolio perspective, EP3636301 functions as a blocking layer if its independent claims are tied to the core commercially marketed regimen or standard formulation. If the independent claim is broader but dependent claims have the main differentiating features, then the practical enforceability depends on how those differentiations survived.
How should an investor or R&D team use EP3636301 to assess competitive positioning?
1) Map EP3636301 to “design space” decision variables
For each claim variable category, score which is likely critical:
- Drug entity definition (active ingredient, salt/form)
- Composition definition (excipients, ratios, dissolution-related attributes)
- Dosage regimen (amount, frequency, duration)
- Treatment indication or patient subset
Then compare to competitor design choices typically made in Europe:
- Switching to a different salt/polymorph
- Reframing regimen to a non-matching schedule
- Using an alternative formulation with different dissolution or particle properties
2) Identify whether EP3636301 is a “core barrier” or “secondary barrier”
In practice:
- Core barrier if independent claims match the standard of care or the marketed formulation/regimen.
- Secondary barrier if independent claims are broad but likely vulnerable, while enforceable value comes from narrower dependent claims.
3) Run an EPO-style “single reference” novelty screen
Validity risk is highest when a single publication covers the full combination of claim elements. If EP3636301’s novelty relies on a multi-element combination (drug + regimen + formulation feature), competitors will search for a reference that bundles all elements.
Key takeaways
- EP3636301’s enforceable reach is determined by its independent claims, with dependent claims likely providing the strongest claim delimitations under EPO practice.
- The landscape around EP3636301 is dominated by predictable “clusters” in European drug patenting: salt/polymorph and form choices, dosing regimen variants, and formulation/process improvements.
- Risk and value both turn on whether EP3636301’s distinguishing limitations align with (1) the commercially used regimen and (2) the standard formulation constraints that competitors would otherwise need to match for regulatory approval.
- For R&D and investment screening, treat EP3636301 as a claim-variable matrix: salt/form, regimen, and formulation parameters are the highest-yield levers for design-around assessment and prior art searches.
FAQs
1) Is EP3636301 more likely to be a regimen patent or a formulation patent?
EP drug family drafting in this area typically mixes composition and use/regimen layers; the decisive answer depends on the independent claim type within EP3636301. In enforcement strategy, identify whether the independent claim requires a specific schedule or specific formulation parameters.
2) What is the typical EPO design-around path against patents like EP3636301?
Design-around usually targets the claim’s critical variable: switching salt/polymorph/form, changing dosing schedule, or altering formulation to fall outside parameter/compositional boundaries.
3) How does EPO novelty analysis usually treat “effective amount” and dosage language?
EPO novelty can be strict when earlier art does not disclose the same dosing specifics. If the claim uses broad dosing terms, novelty can still fail if prior art provides a direct and unambiguous teaching of the same regimen parameters.
4) Which claim features typically matter most during infringement analysis in Europe?
For composition claims, the presence of the claimed components/parameters; for use claims, the medically claimed treatment steps and conditions; for regimen claims, dose amounts and timing.
5) How should EP3636301 be used in a portfolio against generic entry?
Treat it as a blocking layer only if its independent claims track the marketed regimen/formulation. Otherwise, its value may depend on narrower dependent claims.
References
[1] European Patent Office. European Patent Register for EP3636301 (publication and legal status data). https://register.epo.org/
[2] European Patent Office. Guidelines for Examination in the EPO (EPC claim interpretation, novelty and inventive step frameworks). https://www.epo.org/law-practice/legal-texts/guidelines.html
[3] European Patent Convention (EPC). Articles 54, 56, 84, 123(2). https://www.epo.org/law-practice/legal-texts/epc.html
